Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

NCT05912062 · clinicaltrials.gov ↗

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Neoplasms
Breast Cancer

Interventions

DRUG: Trastuzumab (neoadjuvant)
DRUG: Pertuzumab (neoadjuvant)
DRUG: Paclitaxel (neoadjuvant)

Sponsor

Institut Català d'Oncologia

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]